Skip to main content

Lab Notes: Teleflex making acquisition valued at up to $300M; Vyant Bio files delayed quarterly report

A Berwyn biopharm firm dosed the first patient in a late-stage clinical trial testing its lead new drug candidate in patients with Parkinson's disease.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.